UPTRAVI® (selexipag) resources
![[object Object]](https://eu-images.contentstack.com/v3/assets/blt8364eef06c17d9d1/blt616cf1baaa5402b4/614c548a2681e836f5bd28cc/UPTRAVI.png?width=1920&height=361&format=webp&quality=50)
On this page you will find useful information regarding which patients should be initiated on UPTRAVI®, guidance on prescribing and administering UPTRAVI®, access to the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines and 2018 World Symposium on Pulmonary Hypertension proceedings, and recommendations for screening and diagnosing patients with scleroderma or congenital heart disease (CHD) and suspected pulmonary arterial hypertension (PAH).
Prescribing UPTRAVI®
UPTRAVI® SmPC and patient information leaflet
Access the UPTRAVI® SmPC and patient information leaflet.
UPTRAVI® titration guide
Guidance on correctly starting your patient on their UPTRAVI® journey.
UPTRAVI® patient guide
The My UPTRAVI® Treatment Guide explains the dosing process and supports patients along their UPTRAVI® journey.
PAH guidelines and organisations
2015 ESC/ERS guidelines
2018 WSPH proceedings
PHA Europe
Identifying PAH in patients with scleroderma
Scleroderma information guide
Learn how PAH can impact patients with scleroderma.
Scleroderma referral guide
Learn about the investigation and referral pathways for patients with scleroderma and suspected PAH.
Identifying PAH in patients with CHD
CHD information guide
Learn how PAH can impact patients with CHD.
CHD referral guide
Learn about the investigation and referral pathways of patients with CHD and suspected PAH.
Continue reading
Efficacy
Discover how UPTRAVI® can provide long-term benefits for patients with PAH.[1]
Safety and tolerability
UPTRAVI® has a well-characterised and generally manageable safety profile.[1][2]
Initiation and dosing
Adding UPTRAVI® is recommended at the first sign of intermediate risk.[3][4]
Request medical information
Contact a Janssen representative
Stay in touch
CHD, congenital heart disease; ERS, European Respiratory Society; ESC, European Society of Cardiology; PAH, pulmonary arterial hypertension; PHA, Pulmonary Hypertension Association; WSPH, World Symposium on Pulmonary Hypertension
UPTRAVI® PRESCRIBING INFORMATION AND ADVERSE EVENT REPORTING
CP-220222 | May 2021